The 36-month beta value for OVID is at 0.26. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for OVID is 55.62M, and currently, shorts hold a 1.27% of that float. The average trading volume for OVID on February 12, 2025 was 369.30K shares.
OVID) stock’s latest price update
The stock of Ovid Therapeutics Inc (NASDAQ: OVID) has decreased by -10.33 when compared to last closing price of 0.64.Despite this, the company has seen a loss of -13.17% in its stock price over the last five trading days. globenewswire.com reported 2025-02-05 that NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET.
OVID’s Market Performance
Ovid Therapeutics Inc (OVID) has seen a -13.17% fall in stock performance for the week, with a -29.85% decline in the past month and a -55.72% plunge in the past quarter. The volatility ratio for the week is 9.08%, and the volatility levels for the past 30 days are at 9.59% for OVID. The simple moving average for the past 20 days is -17.78% for OVID’s stock, with a -58.45% simple moving average for the past 200 days.
Analysts’ Opinion of OVID
B. Riley Securities, on the other hand, stated in their research note that they expect to see OVID reach a price target of $9. The rating they have provided for OVID stocks is “Buy” according to the report published on April 30th, 2024.
H.C. Wainwright gave a rating of “Buy” to OVID, setting the target price at $9 in the report published on April 29th of the previous year.
OVID Trading at -35.33% from the 50-Day Moving Average
After a stumble in the market that brought OVID to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.96% of loss for the given period.
Volatility was left at 9.59%, however, over the last 30 days, the volatility rate increased by 9.08%, as shares sank -28.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.18% lower at present.
During the last 5 trading sessions, OVID fell by -13.17%, which changed the moving average for the period of 200-days by -81.72% in comparison to the 20-day moving average, which settled at $0.7002. In addition, Ovid Therapeutics Inc saw -38.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OVID starting from ALEXANDER MARGARET A., who purchase 6,810 shares at the price of $0.73 back on Jan 27 ’25. After this action, ALEXANDER MARGARET A. now owns 34,935 shares of Ovid Therapeutics Inc, valued at $4,971 using the latest closing price.
LEVIN JEREMY M, the CEO of Ovid Therapeutics Inc, purchase 18,248 shares at $2.76 during a trade that took place back on Mar 18 ’24, which means that LEVIN JEREMY M is holding 3,616,715 shares at $50,364 based on the most recent closing price.
Stock Fundamentals for OVID
Current profitability levels for the company are sitting at:
- -109.8 for the present operating margin
- -0.09 for the gross margin
The net margin for Ovid Therapeutics Inc stands at -51.46. The total capital return value is set at -0.76. Equity return is now at value -36.60, with -28.55 for asset returns.
Based on Ovid Therapeutics Inc (OVID), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -3.84. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -0.05.
Currently, EBITDA for the company is -57.69 million with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 64.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.66.
Conclusion
In conclusion, Ovid Therapeutics Inc (OVID) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
